Chemical stabilization of a Δ9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: Role of microenvironment pH

AAPS PharmSciTech

Volumn 7, Issue 3, 2006, Pages 1-12

  Munjal, Manish ^a   ElSohly, Mahmoud A ^a,b   Repka, Michael A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

9 tetrahydrocannabinol hemisuccinate; Chemical degradation; Hot melt; pH microenvironment; Plasticizers; Polyethylene oxide; Polymer; Prodrug

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; CANNABINOID DERIVATIVE; DRONABINOL; DRONABINOL HEMISUCCINATE; DRUG ADDITIVE; MACROGOL 400; PLASTICIZER; PRODRUG; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; DRUG CARRIER; DRUG DERIVATIVE; MACROGOL DERIVATIVE; TETRAHYDROCANNABINOL;

ARTICLE; CONTROLLED STUDY; DEGRADATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; HEATING; MELTING POINT; MICROENVIRONMENT; PH; STORAGE TEMPERATURE; CHEMISTRY; DRUG DELIVERY SYSTEM; PHARMACEUTICS; TEMPERATURE;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; POLYETHYLENE GLYCOLS; PRODRUGS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TETRAHYDROCANNABINOL; VITAMIN E;

EID: 33748755972     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070371     Document Type: Article

References (28)

1. Munjal M, Repka MA. Chemical stabilization of an unstable tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method [abstract]. AAPS J [serial online]. 2004; Abstract R6085.
2. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126:791-798.
3. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416.
4. Doyle E, Spence AA. Cannabis as a medicine? Br J Anaesth. 1995;74:359-361.
5. Agurell S, Halldin M, Lindgren J, et al. Pharmacokinetics and metabolism of Δ-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38:21-34.
6. Pop E. Nonpsychotropic synthetic cannabinoids. Curr Pharm Des. 2000;6:1347-1359.
7. ElSohly MA, Stanford DF, Harland EC, et al. Rectal bioavailability of Δ-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci. 1991;80:942-945.
8. ElSohly MA, Little TLJ, Hikal A, Harland E, Stanford DF, Walker L. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav. 1991;40:497-502.
9. Perlin E, Smith CG, Nichols AI, et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the Rhesus monkey. J Pharm Sci. 1985;74:171-174.
10. Mattes RD, Shaw LM, Edling-Owens J, Engelman K, Elsohly MA. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav. 1993;44:745-747.
11. 8-tetrahydrocannabinol hemisuccinate in semi-aqueous solvents. Arch Pharm Chem (Kbh). 1985;13:53-57.
12. 9-THC. US patent 5 389 375. May 21, 1993.
13. Zhang F, McGinity JW. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharm Dev Technol. 1999;4:241-250.
14. Repka MA, Gutta K, Prodduturi S, Munjal M, Stodghill SP. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur J Pharm Biopharm. 2005;59:189-196.
15. Repka MA, Gerding TG, Repka SL, McGinity JW, Influence of plasticizers and drugs on the physical-mechanical properties of hydroxypropylcellulose films prepared by hot-melt extrusion. Drug Dev Ind Pharm. 1999;25:625-633.
16. Crowley MM, Zhang F, Koleng JJ, McGinity JW. Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials. 2002;23:4241-4248.
17. 9-tetrahydrocannabinol produced by a hot-melt method. I. Chemical and thermal stability during processing. J Pharm Sci. In press.
18. Heng PWS, Chan LW, Ong KT. Influence of storage conditions and type of plasticizers on ethylcellulose and acrylate films formed from aqueous dispersions. J Pharm Pharm Sci. 2003;6:334-344.
19. Banker GS. Film coating theory and practice. J Pharm Sci. 1966;55:81-89.
20. Morflex Inc. The role of plasticizers as functional excipients in harmaceutical dosage forms prepared by hot-melt extrusion [Pharmaceutical Coatings Bulletin 102-6]. 2004. Greensboro, NC: Morflex Inc. Available at: http://www.morflex.com/pdf/Bull02.6.pdf. Accessed: May 30, 2006.
21. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution. J Pharm Sci. 2005;94:2463-2474.
22. Mendenhall DW. Stability of parenterals. Drug Dev Ind Pharm. 1984;10:1297-1342.
23. Strickley RG, Visor GC, Lin L, Gu L. An unexpected pH effect on the stability of moexipril lyophilized powder. Pharm Res. 1989;6:971-975.
24. Carstensen JT, Kothari RC. Solid-state decomposition of alkoxyfuroic acids in the presence of microcrystalline cellulose. J Pharm Sci. 1983;72:1149-1154.
25. Usui F, Carstensen JT. Interactions in the solid state. I. Interactions of sodium bicarbonate and tartaric acid under compressed conditions. J Pharm Sci. 1985;74:1293-1297.
26. Badawy SI, Williams RC, Gilbert DL. Chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms. J Pharm Sci. 1999;88:428-433.
27. Badawy SIF, Williams RC, Gilbert DL. Effect of different acids on solid-state stability of an ester prodrug of a IIb/IIIa glycoprotein receptor antagonist. Pharm Dev Technol. 1999;4:325-331.
28. Hsu CH, Jay M, Bummer PM, Lehmler HJ. Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation. Pharm Res. 2003;20:918-925.